TGThomas Clark Gamblin

Thomas Clark Gamblin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas Clark Gamblin has a total of 344 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gastrointestinal Cancer Surgery in Patients on Maintenance Hemodialysis: A Prisma Guided Systematic Review and Propensity Score Matched Cohort Analysis

    by Ali Abdelhady, Yara Sakr, Rayner P. Cardoso, Eman Zineldin, Courtney Scaife, Marshall Baker, Erin Ward, T. Clark Gamblin

    Background: Patients receiving maintenance hemodialysis (HD) have limited physiologic reserve and high competing cardiometabolic risk, yet surgery remains central to cure for many gastrointestinal (GI) malignancies. Evidence describing oncologic surgery in this population is fragmented across cancer sites and data sources. Methods: A PRISMA guided systematic review of adult patients on maintenance HD undergoing resection for GI malignancy was performed. The review searched PubMed, Embase, Web of Science, and CENTRAL through March 2026 and included comparative observational studies reporting perioperative or long‐term outcomes. In parallel, a propensity‐score matched TriNetX cohort of adults undergoing major GI cancer surgery between 2010 and 2025. HD was defined by preoperative ESRD and dialysis dependence codes. Patients were matched 1:1 on age, sex, race, and ethnicity. The primary outcome was 30‐day mortality; secondary outcomes were 30‐day sepsis, pneumonia, and acute myocardial infarction (AMI). Results: The review included 20 studies after screening 1,744 deduplicated records and 83 full texts. Colorectal surgery provided the most robust evidence: dialysis was associated with markedly higher mortality and serious morbidity, and a published meta‐analysis of colorectal surgery estimated a pooled mortality odds ratio (OR) of 4.12. Gastric, pancreatic, and hepatobiliary reports were smaller but showed the same direction of effect, with frequent infectious and cardiovascular complications and substantial competing non‐cancer mortality. In the current TriNetX analysis, 3,757 HD patients were matched to 3757 non‐HD controls. Thirty‐day mortality was 11.4% in HD patients versus 3.0% in controls (OR: 4.21, 95% CI: 3.40–5.22). HD patients also had higher rates of sepsis (14.1% vs. 3.9%; OR 4.06), pneumonia (8.1% vs. 2.2%; OR: 4.02), and AMI (4.3% vs. 0.9%; OR: 5.18). Conclusions: Across GI cancer operations, maintenance HD identifies a very high‐risk surgical phenotype. The dominant short‐term pattern is excess death, infection, and cardiopulmonary morbidity; the dominant long‐term pattern is competing non‐cancer mortality. Surgery remains appropriate for selected patients with resectable disease, but perioperative dialysis timing, multidisciplinary optimization, and treatment in experienced centers are critical.

  • Natural history of undifferentiated pleomorphic sarcoma: Experience from the US Sarcoma Collaborative

    by Eleftherios A. Makris, Thuy B. Tran, Daniel J. Delitto, Byrne Lee, Cecilia G. Ethun, Valerie Grignol, J. Harrison Howard, Meena Bedi, T. Clark Gamblin, Jennifer Tseng, et al.

    Background: Undifferentiated pleomorphic sarcoma (UPS) is a relatively rare but aggressive neoplasm. We sought to utilize a multi‐institutional US cohort of sarcoma patients to examine predictors of survival and recurrence patterns after resection of UPS.Methods: From 2000 to 2016, patients with primary UPS undergoing curative‐intent surgical resection at seven academic institutions were retrospectively reviewed. Epidemiologic and clinicopathologic factors were reviewed by site of origin. Overall survival (OS), recurrence‐free survival (RFS), time‐to‐locoregional (TTLR), time‐to‐distant recurrence (TTDR), and patterns of recurrence were analyzed.Results: Of the 534 UPS patients identified, 53% were female, with a median age of 60 and median tumor size of 8.5 cm. The median OS, RFS, TTLR, and TTDR for the entire cohort were 109, 49, 86, and 46 months, respectively. There were no differences in these survival outcomes between extremity and truncal UPS. Compared with truncal, extremity UPS were more commonly amenable to R0 resection (87% vs. 75%, p = 0.017) and less commonly associated with lymph node metastasis (1% vs. 6%, p = 0.031). R0 resection and radiation treatment, but not site of origin (extremity vs. trunk) were independent predictors of OS and RFS. TTLR recurrence was shorter for UPS resected with a positive margin and for tumors not treated with radiation.Conclusion: For patients with resected extremity and truncal UPS, tumor size >5 cm and positive resection margin are associated with worse survival OS and RFS, irrespectively the site of origin. R0 surgical resection and radiation treatment may help improve these survival outcomes.


  • Staging for Gallbladder Cancer

    by Chad E. Cragle, T. Clark Gamblin

  • Immune checkpoint inhibitors in hepatocellular carcinoma: A review of current clinical trials

    by Adriana C. Gamboa, David A. Kooby, Shishir K. Maithel, T. Clark Gamblin

    Hepatocellular carcinoma (HCC) is the most common primary liver cancer with a poor prognosis due to advanced disease presentation or recurrence despite curative‐intent resection. Since the approval of sorafenib in 2007, few systemic therapies offered a significant improvement in treatment outcomes. Over the last 3 years, however, rapid advancements in the field of immunotherapy have led to approval of checkpoint inhibitors in 2020 for use in advanced HCC. Since then, a few other clinical trials have shown promising results in the adjuvant and neoadjuvant setting. The objective of this review is to summarize data from existing clinical trials evaluating the use of systemic immune checkpoint inhibitors in HCC and to follow the natural evolution of this development across the metastatic, adjuvant, and neoadjuvant landscapes.


  • Outcomes of plastic surgical reconstruction in extremity and truncal soft tissue sarcoma: Results from the US Sarcoma Collaborative

    by Sam Z. Thalji, Cecilia G. Ethun, Susan Tsai, T. Clark Gamblin, Callisia N. Clarke, Meena Bedi, David King, John LoGiudice, George Poultsides, Valerie P. Grignol, et al.

    Background: This study aimed to define how utilization of plastic surgical reconstruction (PSR) affects perioperative outcomes, locoregional recurrence‐free survival (LRRFS), and overall survival (OS) after radical resection of extremity and truncal soft tissue sarcoma (ETSTS). The secondary aim was to determine factors associated with PSR.Methods: Patients who underwent resection of ETSTS between 2000 and 2016 were identified from a multi‐institutional database. PSR was defined as complex primary closure requiring a plastic surgeon, skin graft, or tissue‐flap reconstruction. Outcomes included PSR utilization, postoperative complications, LRRFS, and OS.Results: Of 2750 distinct operations, 1060 (38.55%) involved PSR. Tissue‐flaps (854, 80.57%) were most commonly utilized. PSR was associated with a higher proportion of R0 resections (83.38% vs. 74.42%, p < 0.001). Tissue‐flap PSR was associated with local wound complications (odds ratio: 1.81, confidence interval: 1.21–2.72, p = 0.004). Neither PSR nor postoperative complications were independently associated with LRRFS or OS. High‐grade tumors (1.60, 1.13–2.26, p = 0.008) and neoadjuvant radiation (1.66, 1.20–2.30, p = 0.002) were associated with the need for PSR.Conclusion: Patients with ETSTS undergoing resection with PSR experienced acceptable rates of complications and a higher rate of negative margins, which were associated with improved LRRFS and OS. High tumor grade and neoadjuvant radiation were associated with requirement of PSR.


  • 57: CHARACTERISTICS OF HIGH PERFORMING FACILITIES TREATING PATIENTS WITH COLORECTAL LIVER METASTASES: AN ANALYSIS OF THE NATIONAL CANCER DATABASE

    by Chad Barnes, Erin Ward, Jennifer Merrill, Nathaniel Verhagen, Veronica Loy, Callisia N. Clarke, Kathleen Christians, Ugwuji N. Maduekwe, Thomas C. Gamblin, Anai N. Kothari

  • Two-Stage Hepatectomy for Bilateral Colorectal Liver Metastases: A Multi-institutional Analysis

    by Mariana I. Chavez, Sepideh Gholami, Bradford J. Kim, Georgios A. Margonis, Cecilia G. Ethun, Susan Tsai, Kathleen K. Christians, Callisia Clarke, Harveshp Mogal, Shishir K. Maithel, et al.

    Two-stage hepatectomy (TSH) is an important tool in the management of bilateral colorectal liver metastases (CRLM). This study sought to examine the presen


  • Impact of resection margin on outcomes in high‐grade soft tissue sarcomas of the extremity—A USSC analysis

    by Konstantinos Chouliaras, Nathan Patel, Rebecca Senehi, Cecilia G. Ethun, George Poultsides, Valerie Grignol, Thomas Clark Gamblin, Kevin K. Roggin, Ryan C. Fields, Ralph D'AGostino, et al.

    Background: The optimal margin of resection for high‐grade extremity sarcomas and its impact on survival has long been questioned in the setting of adjuvant radiotherapy. The objective of this study was to investigate the impact of resection status on recurrence and survival.Methods: All patients with primary, nonmetastatic, high‐grade extremity sarcomas that underwent surgical resection from January 2000 to April 2016 in the U.S. Sarcoma Collaborative (USSC) were retrospectively reviewed. Recurrence patterns, recurrence‐free survival (RFS), and overall survival (OS) were examined in multivariate analyses (MVA).Results: A cohort of 959 patients was identified with a median follow‐up of 34.7 months from diagnosis. R0 resection was achieved in 86.7% (831) while R1 resection in 13.3% (128). Locoregional recurrence for R0 and R1 groups occurred in 9.1% (76) versus 14.8% (19; p = .05) while distant recurrence occurred in 24.7% (205) versus 26.6% (34; p = .65), respectively. Median RFS was 171.2 versus 48.5 (p = .01) while median OS was 149.8 versus 71.5 months (p = .02) for the R0 versus R1 group, respectively. On MVA, female gender (hazard ratio [HR] = 0.69, p = .007) and adjuvant radiotherapy (0.7, p = .04) were associated with improved OS, whereas older age (HR = 1.03, p < .001) and tumor size (HR = 1.01, p < .001) were associated with worse OS. R0 resection status was associated with improved locoregional RFS (HR = 0.56, p = .03) but not with distant RFS (HR = 0.84, p = .4) or OS (HR = 0.7, p = .052).Conclusions: In high‐grade extremity sarcomas, tumor size and gender are predictive of OS while R0 resection status is associated with improved locoregional recurrence rate without a significant impact on distant RFS or OS.


  • Comparison of overall survival in gallbladder carcinoma at academic versus community cancer centers: An analysis of the National Cancer Data Base

    by Chrissy Liu, Lisa Rein, Callisia Clarke, Harveshp Mogal, Susan Tsai, Kathleen K. Christians, T. C. Gamblin

    Background and Objectives: Gallbladder carcinoma (GBC) has a poor prognosis. Studies demonstrated that teaching facilities may provide a lower risk of mortality in patients undergoing pancreatic and colon resection vs nonteaching facilities. We hypothesized that survival rates are higher in academic cancer centers (ACCs) vs community cancer centers (CCCs).Methods: Patients with all stages of GBC were identified from the National Cancer Database (2007‐2012). Propensity score matching adjusted for selection bias. Descriptive statistics were calculated for all variables. Overall survival (OS) was compared by facility type (ACC vs CCC) and case volume (low vs high) via multivariable Cox proportional hazards regression.Results: A total of 7967 patients met the inclusion criteria. Following propensity matching, 2801 patients were analyzed from each facility type. Median OS following surgery was higher for ACC (20.99 months, 95% confidence interval [CI], 19.61‐22.64, P = .002) than CCC (17.68 months, 95% CI, 16.46‐19.25). Following Cox modeling, GBC treatment at ACCs was a protective factor for OS (adjusted hazard ratio 0.876, 95% CI, 0.801‐0.958, P = .004).Discussion: GBC treatment at ACCs is an independent predictor of OS. High volume ACCs are associated with improved OS compared with low volume ACCs. The site of care and case volume in ACCs may contribute to improved survival outcomes.


  • Outcomes of palliative‐intent surgery in retroperitoneal sarcoma—Results from the US Sarcoma Collaborative

    by Sam Z. Thalji, Susan Tsai, T. Clark Gamblin, Callisia Clarke, Kathleen Christians, John Charlson, Cecilia G. Ethun, George Poultsides, Valerie P. Grignol, Kevin K. Roggin, et al.

    Background and Objectives: Outcomes of palliative‐intent surgery in retroperitoneal sarcomas (RPS) are not well understood. This study aims to define indications for and outcomes after palliative‐intent RPS resection.Methods: Using a retrospective 8‐institution database, patients undergoing resection of primary/recurrent RPS with palliative intent were identified. Logistic regression and Cox‐proportional hazards models were constructed to analyze factors associated with postoperative complications and overall survival (OS).Results: Of 3088 patients, 70 underwent 87 palliative‐intent procedures. Most common indications were pain (26%) and bowel obstruction (21%). Dedifferentiated liposarcoma (n = 17, 24%), leiomyosarcoma (n = 13, 19%) were predominant subtypes. Median OS was 10.69 months (IQR, 3.91‐23.23). R2 resection (OR, 8.60; CI, 1.42‐52.15; P = .019), larger tumors (OR, 10.87; CI, 1.44‐82.11; P = .021) and low preoperative albumin (OR, 0.14; CI, 0.04‐0.57; P = .006) were associated with postoperative complications. Postoperative complications (HR, 1.95; CI, 1.02‐3.71; P = .043) and high‐grade histology (HR, 6.56; CI, 1.72‐25.05; P = .006) rather than resection status were associated with reduced OS. However, in R2‐resected patients, development of postoperative complications significantly reduced survival (P = .042).Conclusions: Postoperative complications and high‐grade histology rather than resection status impacts survival in palliative‐intent RPS resections. Given the higher incidence of postoperative complications which may diminish survival, palliative‐intent R2 resection should be offered only after cautious consideration.